ERGIC1

Across TCGA pan-cancer cohorts, ERGIC1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ERGIC1 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ERGIC1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ERGIC1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where ERGIC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.729	0.940	<.001	48	view →
LSCC	DFS	Tertile	II,III,IV	0.498	0.903	.003	16	view →
HNSC	DFS	Median	IV	0.892	0.668	.029	6	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
LUAD	DFS	Quartile	All	0.853	0.989	.040	2	view →
UCEC	OS	Median	All	0.984	0.910	.030	2	view →
GBM	OS	Tertile	All	0.790	0.876	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ERGIC1–CCRCC (OS)

Open the CCRCC breakdown →